NLM Digital Collections

Search

Start Over Subjects Medicare Part B -- economics ✖Remove constraint Subjects: Medicare Part B -- economics

2. Medicare Part B drug payments: impact of price substitutions based on 2014 average sales prices

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, August 2017
Subject(s):
Drug Costs
Insurance, Health, Reimbursement
Insurance, Pharmaceutical Services
Medicare Part B -- economics
Cost Savings
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

3. Medicare payments for clinical diagnostic laboratory tests in 2016: year 3 of baseline data

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, September 2017
Subject(s):
Clinical Laboratory Techniques -- economics
Insurance, Health, Reimbursement
Medicare Part B -- economics
Prospective Payment System
Rate Setting and Review
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

4. Excluding noncovered versions when setting payment for two Part B drugs would have resulted in lower drug costs for Medicare and its beneficiaries

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, November 2017
Subject(s):
Drug Costs
Insurance, Pharmaceutical Services -- economics
Medicare Part B -- economics
Prospective Payment System
Abatacept -- economics
Certolizumab Pegol -- economics
Cost Savings
Injections -- economics
Self Care -- economics
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)
Healthcare common procedure coding system

5. Followup review: CMS's management of the quality payment program

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, December 2017
Subject(s):
Insurance, Health, Reimbursement
Medical Informatics
Medicare Part B -- economics
Quality of Health Care -- economics
Reimbursement, Incentive
Diffusion of Innovation
Fraud -- prevention & control
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

6. Medicare Part B drug payments: impact of price substitutions based on 2016 average sales prices

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, August 2018
Subject(s):
Drug Costs
Insurance, Health, Reimbursement
Medicare Part B -- economics
Cost Savings
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

7. Medicare payments for clinical diagnostic laboratory tests in 2017: year 4 of baseline data

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, September 2018
Subject(s):
Clinical Laboratory Techniques -- economics
Insurance, Health, Reimbursement
Medicare Part B -- economics
Prospective Payment System
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

10. Medicare physician payment: are we getting what we pay for? : Are we paying for what we want? : Invited testimony, Energy and Commerce Committee, Subcommittee on Health, U.S. House of Representatives hearing on "Medicare Physician Payment : how to Build a Payment System That Provides Quality, Efficient Care for Medicare Beneficiaries"

Publication:
[New York, N.Y.] : Commonwealth Fund, [2006]
Subject(s):
Insurance, Health, Reimbursement
Medicare Part B -- economics
Prospective Payment System -- economics
Cost Control
Health Services Accessibility -- economics
Quality of Health Care -- economics
Medical Informatics -- economics
Physician Incentive Plans -- economics
United States

15. Medicare Part B: Medicare represented at least half of the market for 22 of the 84 most expensive drugs in 2015 : report to Congressional requesters

Publication:
Washington, DC : United States Government Accountability Office, December 2017
Subject(s):
Drug Costs
Health Care Sector
Health Expenditures
Medicare Part B -- economics
Insurance, Health, Reimbursement
Medicare Part B -- statistics & numerical data
Humans
United States

16. Physician payment: current system and opportunities for reform

Publication:
Washington, D.C. : AARP Public Policy Institute, c2009
Subject(s):
Health Care Reform
Physicians
Prospective Payment System -- organization & administration
Reimbursement Mechanisms -- organization & administration
Medicare Part B -- economics
Patient-Centered Care
Primary Health Care -- economics
Humans
France
Germany
United Kingdom
Japan
United States

17. Analysis of alternative approaches to increasing Part B financial assistance to Medicare beneficiaries with low incomes

Author(s):
Gangopadhyaya, Anuj, author
Holahan, John, author
Shartzer, Adele, author
Garrett, Bowen, author
Publication:
Washington, DC : Urban Institute, December 2022
Subject(s):
Health Equity -- economics
Health Policy
Medicare Part B -- economics
Poverty -- statistics & numerical data
United States

19. “Lesser-of” payment policies and the use of physicians’ services among dual-eligible beneficiaries

Author(s):
Hayford, Tamara, author
Niu, Xiaotong, author
Decker, Sandra Lynn, author
Publication:
[Washington, DC] : Congressional Budget Office, January 2023
Subject(s):
Cost Sharing -- economics
Dual MEDICAID MEDICARE Eligibility
Facilities and Services Utilization -- statistics & numerical data
Insurance, Health Reimbursement -- economics
Insurance, Physician Services -- economics
Medicare Part B -- economics
United States

20. Summary of recent and proposed changes to Medicare prescription drug coverage and reimbursement

Author(s):
Cubanski, Juliette, author
Publication:
Menlo Park, CA : Henry J. Kaiser Family Foundation, February 2018
Subject(s):
Medicare Part B -- economics
Medicare Part D -- economics
Prescription Drugs -- economics
Formularies as Topic
Insurance, Health, Reimbursement -- economics
Medicare Part B -- legislation & jurisprudence
Medicare Part D -- legislation & jurisprudence
Humans
United States

21. Medicare Part B drug payments: impact of price substitutions based on 2018 average sales prices

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, August 2020
Subject(s):
Cost Control -- legislation & jurisprudence
Drug Substitution -- economics
Government Regulation
Medicare Part B -- economics
United States
United States. Department of Health and Human Services

22. Some manufacturers reported inaccurate drug product data to CMS

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, September 2020
Subject(s):
Data Accuracy
Drug Industry -- legislation & jurisprudence
Government Regulation
Medicare Part B -- economics
Pharmaceutical Preparations -- economics
United States
United States. Department of Health and Human Services

25. COVID-19 tests drove an increase in total Medicare Part B spending on lab tests in 2020, while use of non-COVID-19 tests decreased significantly

Publication:
Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, December 2021
Subject(s):
Clinical Laboratory Techniques -- economics
COVID-19 Testing -- economics
Government Regulation
Medicare Part B -- economics
United States
United States. Department of Health and Human Services

26. High-expenditure Medicare drugs often qualified for Orphan Drug Act incentives designed to encourage the development of treatments for rare diseases

Publication:
Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, September 2021
Subject(s):
Drug Development -- legislation & jurisprudence
Government Regulation
Medicare Part B -- economics
Medicare Part D -- economics
Orphan Drug Production -- economics
United States
United States. Department of Health and Human Services

27. Medicare Part B drug payments: impact of price substitutions based on 2017 average sales prices

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, August 2019
Subject(s):
Cost Control
Cost Savings
Drug Costs
Insurance, Health, Reimbursement
Medicare Part B -- economics
Reimbursement Mechanisms
Economics, Pharmaceutical
Humans
United States
Centers for Medicare & Medicaid Services (U.S.)

28. CBO's Medicare beneficiary cost-sharing model: a technical description

Author(s):
Duchovny, Noelia, author
Kowalczyk, Jamease, author
Laughery, Scott, author
Sajewski, Sarah, author
Publication:
[Washington, DC] : Congressional Budget Office, October 2019
Subject(s):
Budgets
Cost Sharing
Fee-for-Service Plans -- economics
Medicare -- economics
Models, Economic
Deductibles and Coinsurance -- economics
Federal Government
Medicare Part A -- economics
Medicare Part B -- economics
Humans
United States

29. Medicare Part B drugs: trends in spending and utilization, 2008-2021

Author(s):
Nguyen, Nuguyen X., author
Olsen, T. Anders, author
Sheingold, Steven, author
De Lew, Nancy, author
Publication:
Washington, D.C. : Office of the Assistant Secretary for Planning and Evaluation, June 9, 2023
Subject(s):
Cost Control
Drug Utilization -- statistics & numerical data
Drug Utilization -- trends
Health Expenditures -- statistics & numerical data
Health Expenditures -- trends
Medicare Part B -- economics
United States
United States.